Zhejiang Xinguang Pharmaceutical Co Ltd operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Zhejiang Xinguang Pharmaceutical Co Ltd with three other
companies in this sector in CHINA :
Shenzhen Chipscreen Biosciences Co Ltd
sales of 269.47 million Chinese Renmimbi [US$42.21 million]
of which 100%
Jilin Zixin Pharmaceutical Industrial Co Ltd
(285.54 million Chinese Renmimbi [US$44.73 million]
of which 95%
was Chinese patent medicines), and
Tus Pharmaceutical Group Co Ltd
(275.09 million Chinese Renmimbi [US$43.09 million]
of which 92%
was Chinese medicine health care production ).
During the second
quarter of 2021, sales at Zhejiang Xinguang Pharmaceutical Co Ltd totalled
62.58 million Chinese Renmimbi.
an increase of 9.0%
from the 57.43 million Chinese Renmimbi in sales at the company during the second quarter of 2020.
During the first two
quarters of 2021, sales totalled 159.50 million Chinese Renmimbi, which is
than through the first two quarters of 2020.
There appears to be at least some degree of seasonality in the sales at Zhejiang Xinguang Pharmaceutical Co Ltd: during 5 of the previous 6
years, sales were highest during the first quarter.
The exception to this was during 2020, when the
third quarter was the best quarter, accounting for
30% of sales (during that same year, the
first quarter accounted for 25% of sales).
Zhejiang Xinguang Pharmaceutical Co Ltd reported sales of 283.08 million Chinese Renmimbi (US$44.34 million)
December of 2020.
decrease of 2.8%
versus 2019, when the company's sales were 291.26 million Chinese Renmimbi.
The sales level in 2020 was fairly close to the level five years ago: in 2015, Zhejiang Xinguang Pharmaceutical Co Ltd had sales
of 311.44 million Chinese Renmimbi.
Contributing to the drop in overall sales was the 13.2% decline
in Shenjin Dan Capsule, from 31.51 million Chinese Renmimbi to 27.36 million Chinese Renmimbi.
There were also decreases in sales in
Huangqi Shengmai Drink (down 3.9% to 215.92 million Chinese Renmimbi)
However, these declines were partially offset by the increase in sales of
American Ginseng Oral Solution (up 16.3% to 32.09 million Chinese Renmimbi)
Other Products (up 2.3% to 7.59 million Chinese Renmimbi)
Other Operations (up 4.6% to 123,470.95 Chinese Renmimbi)